Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| b bit.bioCompany profile Creates functional, human-relevant cells and models for research, drug discovery, and development Creates functional, human-relevant cells and models for research, drug discovery, and development | $50M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| AT AirNexis TherapeuticsCompany profile AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01. AirNexis Therapeutics develops medicines for pulmonary diseases, led by the investigational COPD candidate AN01. | $200M | Series A | Biotech | United States | Investors | |
| V Builds technologies for spatial biology and multi-omics innovation | $48M | Series A | Biotech | United States | Investors | |
| A AbbelightCompany profile Microscopy and nanoscopy systems combining chemistry, optics and analysis for life-science researchers. Microscopy and nanoscopy systems combining chemistry, optics and analysis for life-science researchers. | Undisclosed | Series B | Biotech | France | Investors | |
| ET Enodia TherapeuticsCompany profile Develops small-molecule therapies for targeted protein degradation at the point of synthesis Develops small-molecule therapies for targeted protein degradation at the point of synthesis | €20.7M | Seed | Biotech | France | Investors | |
| E EpiBiologicsCompany profile Develops bispecific antibodies for targeted degradation of extracellular proteins. Develops bispecific antibodies for targeted degradation of extracellular proteins. | $107M | Series B | Biotech | United States | Investors | |
| PD Perceptive DiscoveryCompany profile Provides preclinical and translational solutions for oncology and radiopharmaceutical programs Provides preclinical and translational solutions for oncology and radiopharmaceutical programs | $15M | StrategicUndisclosed | Biotech | United Kingdom | Investors | |
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners | |
| NT Nocion TherapeuticsCompany profile Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. | $23M | Series B+Series B | Biotech | United States | Investors Undisclosed | |
| S STRM.BIOCompany profile Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy | $8M | Seed2Seed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.